Back to Menu
Gastric Cancer Treatment Modalities
1.Endoscopic minimally invasive treatment
EMR/ESD is suitable for early mucosal lesions, preserving gastric function, with a 5-year survival rate exceeding 95%.
2.Surgical treatment
Radical gastrectomy with lymph node dissection; distal, proximal, or total gastrectomy is selected according to tumor location.
3.Laparoscopic minimally invasive surgery
Associated with less trauma and faster recovery; suitable for early-stage and selected advanced gastric cancer, with long-term outcomes comparable to open surgery.
4.Robotic surgical systems
Provide a high-definition 3D view and flexible instrument control, improving the precision of lymph node dissection.
5.Neoadjuvant chemotherapy
Administered preoperatively to downstage tumors and increase R0 resection rates; common regimens include SOX and XELOX.
6.Adjuvant chemotherapy
Administered postoperatively to eradicate micrometastases, reduce recurrence risk, and improve 5-year survival.
7.Targeted therapy
Directed against targets such as HER2 and VEGFR2; genomic testing is required to guide selection and can prolong survival in advanced disease.
8.Immunotherapy
PD-1 inhibitors are used for MSI-H or PD-L1–positive advanced gastric cancer, as monotherapy or in combination with chemotherapy.
9.Radiotherapy
Used for cardia cancer, local recurrence, or palliative pain control, and may be applied as neoadjuvant or adjuvant therapy in selected settings.
10.Intraperitoneal chemotherapy
Used to control peritoneal metastasis and malignant ascites, often combined with systemic chemotherapy.
11.Supportive and symptomatic care
Comprehensive management throughout the treatment course, including nutritional support, pain control, and correction of anemia, to ensure treatment tolerance and quality of life.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that gastric cancer requires individualized, standardized multimodal treatment. Experts highlight that early detection and timely treatment can markedly improve cure rates. An MDT team should develop stage-adapted plans and prioritize rehabilitation and follow-up to maximize survival benefit and quality of life.
Gastric Cancer Treatment Modalities
1.Endoscopic minimally invasive treatment
EMR/ESD is suitable for early mucosal lesions, preserving gastric function, with a 5-year survival rate exceeding 95%.
2.Surgical treatment
Radical gastrectomy with lymph node dissection; distal, proximal, or total gastrectomy is selected according to tumor location.
3.Laparoscopic minimally invasive surgery
Associated with less trauma and faster recovery; suitable for early-stage and selected advanced gastric cancer, with long-term outcomes comparable to open surgery.
4.Robotic surgical systems
Provide a high-definition 3D view and flexible instrument control, improving the precision of lymph node dissection.
5.Neoadjuvant chemotherapy
Administered preoperatively to downstage tumors and increase R0 resection rates; common regimens include SOX and XELOX.
6.Adjuvant chemotherapy
Administered postoperatively to eradicate micrometastases, reduce recurrence risk, and improve 5-year survival.
7.Targeted therapy
Directed against targets such as HER2 and VEGFR2; genomic testing is required to guide selection and can prolong survival in advanced disease.
8.Immunotherapy
PD-1 inhibitors are used for MSI-H or PD-L1–positive advanced gastric cancer, as monotherapy or in combination with chemotherapy.
9.Radiotherapy
Used for cardia cancer, local recurrence, or palliative pain control, and may be applied as neoadjuvant or adjuvant therapy in selected settings.
10.Intraperitoneal chemotherapy
Used to control peritoneal metastasis and malignant ascites, often combined with systemic chemotherapy.
11.Supportive and symptomatic care
Comprehensive management throughout the treatment course, including nutritional support, pain control, and correction of anemia, to ensure treatment tolerance and quality of life.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that gastric cancer requires individualized, standardized multimodal treatment. Experts highlight that early detection and timely treatment can markedly improve cure rates. An MDT team should develop stage-adapted plans and prioritize rehabilitation and follow-up to maximize survival benefit and quality of life.